New weight loss treatment - information for patients
As you may have read or heard in the news, a new weight-loss drug called tirzepatide, also known as Mounjaro, has become available for use in primary care from Monday 23rd June.
In line with NHS England guidance, this new treatment will only be available for patients who have a body mass index (BMI) of 40 or above and have been diagnosed with 4 of the following 5 obesity-related health conditions:
- Type 2 diabetes
- Hypertension
- Cardiovascular disease
- Obstructive sleep apnoea
- Dyslipidemia
Patients are advised that prescriptions will not be provided immediately, and that 23rd June is purely the date from which GPs may wish to begin a discussion with eligible patients about using tirzepatide as part of their overall weight-loss journey.
The Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board is currently working with colleagues in primary care to ensure this new treatment is offered to those patients who fulfil this criteria.
At this time, patients are kindly asked not to contact their GP practice with requests for weight loss treatment.
All patients, including those who may be eligible for the new drug, are continued to be encouraged to access NHS-supported healthy living initiatives, such as diet support and activity groups, as part of their overall weight loss journey.
Published on 26th Jun 2025